The bidirectional association of nonalcoholic fatty liver disease with depression, bipolar disorder, and schizophrenia.

Autor: Jawad MY; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.; Brain and Cognition Discovery Foundation, Toronto, ON, Canada., Meshkat S; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada., Tabassum A; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada., Mckenzie A; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada., Di Vincenzo JD; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada., Guo Z; Brain and Cognition Discovery Foundation, Toronto, ON, Canada., Musavi NB; Liaquat National Medical College, Karachi, Pakistan., Phan L; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada., Ceban F; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.; Brain and Cognition Discovery Foundation, Toronto, ON, Canada., Kwan AT; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.; Brain and Cognition Discovery Foundation, Toronto, ON, Canada.; Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada., Ramachandra R; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.; Brain and Cognition Discovery Foundation, Toronto, ON, Canada., Le GH; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.; Brain and Cognition Discovery Foundation, Toronto, ON, Canada., Mansur RB; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.; Department of Psychiatry, University of Toronto, Toronto, ON, Canada., Rosenblat JD; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.; Department of Psychiatry, University of Toronto, Toronto, ON, Canada., Ho R; Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.; Institute for Health Innovation and Technology (iHealthtech), National University of Singapore, Singapore, Singapore., Rhee TG; Department of Psychiatry, School of Medicine, Yale University, New Haven, CT, USA.; VA New England Mental Illness, Research, Education and Clinical Center (MIRECC), VA Connecticut Healthcare System, West Haven, CT, USA.; Department of Public Health Sciences, School of Medicine, University of Connecticut, Farmington, CT, USA., McIntyre RS; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.; Brain and Cognition Discovery Foundation, Toronto, ON, Canada.; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.
Jazyk: angličtina
Zdroj: CNS spectrums [CNS Spectr] 2023 Oct; Vol. 28 (5), pp. 541-560. Date of Electronic Publication: 2022 Oct 21.
DOI: 10.1017/S1092852922001043
Abstrakt: Nonalcoholic fatty liver disease (NAFLD) is a complex metabolic-inflammatory disease associated with poor outcomes and decreased quality of life. NAFLD is overrepresented in patients with psychiatric disorders like depression, bipolar disorder, and schizophrenia; however, a comprehensive review on NAFLD and psychiatric disorders remains to be delineated. This review endeavors to investigate the association of NAFLD with psychiatric disorders, including shared pathogenesis and future clinical derivatives. Extant literature suggests that patients with psychiatric disorders (in particular, mood disorders) are more susceptible to the development of NAFLD due to multiple reasons, including but not limited to hypothalamic-pituitary-adrenal axis dysregulation, metabolic syndrome, and chronic perceived stress. Moreover, the clinical manifestations of mood disorders (e.g., anhedonia, psychomotor retardation, lifestyle modification, etc.), and potentially long-term treatment with weight-gaining agents, differentially affect these patients, making them more prone to NAFLD. Considering the increased morbidity associated with both mood disorders and NAFLD, our review recommends regular screenings for NAFLD in select patients with mood disorders exhibiting signs of increased risk (i.e., obesity, metabolic syndrome, diabetes, or family history of NAFLD) for better diagnosis and holistic care of both potentially interrelated conditions.
Databáze: MEDLINE